Revolution Medicines’ daraxonrasib produced a major survival improvement in a Phase 3 trial of advanced pancreatic cancer, with median overall survival increasing to 13.2 months versus 6.7 months for chemotherapy. The RAS pathway inhibitor blocks all three RAS family members, aiming to overcome the limitations of prior single-mutant or single-RAS approaches. The Phase 3 RASolute 302 trial enrolled 500 participants, with efficacy consistent across the overall population and a common RAS-mutation subset. Investigators also reported disease progression slowing, with time to disease worsening extending in the daraxonrasib arm compared with standard-of-care treatment. The readout, presented at the American Society of Clinical Oncology annual meeting and published in The New England Journal of Medicine, is being framed by experts as a potential practice-changing shift after years of limited progress for pancreatic cancer patients.